Is MYGN or MNKD more profitable?

MannKind has a net margin of -6.63% compared to Myriad Genetics' net margin of -48.24%. Myriad Genetics' return on equity of -8.51% beat MannKind's return on equity. Company Net Margins Return on Equity Return on Assets Myriad Genetics -48.24% -8.51% -4.48% MannKind -6.63% -11.21% -3.92%

Does the media favor MYGN or MNKD?

In the previous week, MannKind had 15 more articles in the media than Myriad Genetics. MarketBeat recorded 17 mentions for MannKind and 2 mentions for Myriad Genetics. Myriad Genetics' average media sentiment score of 0.84 beat MannKind's score of 0.73 indicating that Myriad Genetics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Myriad Genetics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MannKind 7 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor MYGN or ZBIO?

In the previous week, Zenas BioPharma had 3 more articles in the media than Myriad Genetics. MarketBeat recorded 5 mentions for Zenas BioPharma and 2 mentions for Myriad Genetics. Myriad Genetics' average media sentiment score of 0.84 beat Zenas BioPharma's score of 0.64 indicating that Myriad Genetics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Myriad Genetics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Zenas BioPharma 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor MYGN or OPK?

In the previous week, OPKO Health had 1 more articles in the media than Myriad Genetics. MarketBeat recorded 3 mentions for OPKO Health and 2 mentions for Myriad Genetics. Myriad Genetics' average media sentiment score of 0.84 beat OPKO Health's score of 0.72 indicating that Myriad Genetics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Myriad Genetics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive OPKO Health 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor MYGN or LXRX?

In the previous week, Lexicon Pharmaceuticals had 1 more articles in the media than Myriad Genetics. MarketBeat recorded 3 mentions for Lexicon Pharmaceuticals and 2 mentions for Myriad Genetics. Myriad Genetics' average media sentiment score of 0.84 beat Lexicon Pharmaceuticals' score of 0.47 indicating that Myriad Genetics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Myriad Genetics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Lexicon Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger valuation and earnings, MYGN or GERN?

Geron has lower revenue, but higher earnings than Myriad Genetics. Geron is trading at a lower price-to-earnings ratio than Myriad Genetics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Myriad Genetics $824.50M 0.50 -$365.90M -$4.30 N/A Geron $183.88M 4.05 -$83.50M -$0.11 N/A

Is MYGN or GERN more profitable?

Geron has a net margin of -35.48% compared to Myriad Genetics' net margin of -48.24%. Myriad Genetics' return on equity of -8.51% beat Geron's return on equity. Company Net Margins Return on Equity Return on Assets Myriad Genetics -48.24% -8.51% -4.48% Geron -35.48% -23.31% -10.08%

Does the media favor MYGN or GERN?

In the previous week, Geron had 1 more articles in the media than Myriad Genetics. MarketBeat recorded 3 mentions for Geron and 2 mentions for Myriad Genetics. Myriad Genetics' average media sentiment score of 0.84 beat Geron's score of 0.65 indicating that Myriad Genetics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Myriad Genetics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Geron 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Myriad Genetics (MYGN) Competitors

$4.40 +0.09 (+2.09%)

Closing price 06/3/2026 04:00 PM Eastern

Extended Trading

$4.28 -0.13 (-2.84%)

As of 06/3/2026 07:55 PM Eastern

Compare

MYGN vs. MNKD, ZBIO, OPK, LXRX, and GERN

Should you buy Myriad Genetics stock or one of its competitors? MarketBeat compares Myriad Genetics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Myriad Genetics include MannKind (MNKD), Zenas BioPharma (ZBIO), OPKO Health (OPK), Lexicon Pharmaceuticals (LXRX), and Geron (GERN). These companies are all part of the "biotechnology" industry.

How does Myriad Genetics compare to MannKind?

Myriad Genetics (NASDAQ:MYGN) and MannKind (NASDAQ:MNKD) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, analyst recommendations, valuation, risk, media sentiment and dividends.

MannKind has lower revenue, but higher earnings than Myriad Genetics. MannKind is trading at a lower price-to-earnings ratio than Myriad Genetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Myriad Genetics	$824.50M	0.50	-$365.90M	-$4.30	N/A
MannKind	$348.97M	2.97	$5.86M	-$0.07	N/A

Myriad Genetics currently has a consensus target price of $6.50, suggesting a potential upside of 47.73%. MannKind has a consensus target price of $8.97, suggesting a potential upside of 166.93%. Given MannKind's stronger consensus rating and higher possible upside, analysts clearly believe MannKind is more favorable than Myriad Genetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Myriad Genetics	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
MannKind	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60

MannKind has a net margin of -6.63% compared to Myriad Genetics' net margin of -48.24%. Myriad Genetics' return on equity of -8.51% beat MannKind's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Myriad Genetics	-48.24%	-8.51%	-4.48%
MannKind	-6.63%	-11.21%	-3.92%

Myriad Genetics has a beta of 1.73, meaning that its stock price is 73% more volatile than the broader market. Comparatively, MannKind has a beta of 1.13, meaning that its stock price is 13% more volatile than the broader market.

99.0% of Myriad Genetics shares are held by institutional investors. Comparatively, 49.6% of MannKind shares are held by institutional investors. 1.9% of Myriad Genetics shares are held by insiders. Comparatively, 2.6% of MannKind shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, MannKind had 15 more articles in the media than Myriad Genetics. MarketBeat recorded 17 mentions for MannKind and 2 mentions for Myriad Genetics. Myriad Genetics' average media sentiment score of 0.84 beat MannKind's score of 0.73 indicating that Myriad Genetics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Myriad Genetics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MannKind	7 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

MannKind beats Myriad Genetics on 10 of the 16 factors compared between the two stocks.

How does Myriad Genetics compare to Zenas BioPharma?

Myriad Genetics (NASDAQ:MYGN) and Zenas BioPharma (NASDAQ:ZBIO) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, media sentiment, dividends, analyst recommendations and earnings.

99.0% of Myriad Genetics shares are held by institutional investors. 1.9% of Myriad Genetics shares are held by company insiders. Comparatively, 22.0% of Zenas BioPharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Myriad Genetics currently has a consensus target price of $6.50, indicating a potential upside of 47.73%. Zenas BioPharma has a consensus target price of $44.29, indicating a potential upside of 154.52%. Given Zenas BioPharma's stronger consensus rating and higher probable upside, analysts plainly believe Zenas BioPharma is more favorable than Myriad Genetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Myriad Genetics	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Zenas BioPharma	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56

Myriad Genetics has a beta of 1.73, indicating that its share price is 73% more volatile than the broader market. Comparatively, Zenas BioPharma has a beta of -0.71, indicating that its share price is 171% less volatile than the broader market.

In the previous week, Zenas BioPharma had 3 more articles in the media than Myriad Genetics. MarketBeat recorded 5 mentions for Zenas BioPharma and 2 mentions for Myriad Genetics. Myriad Genetics' average media sentiment score of 0.84 beat Zenas BioPharma's score of 0.64 indicating that Myriad Genetics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Myriad Genetics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Zenas BioPharma	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Myriad Genetics has higher revenue and earnings than Zenas BioPharma. Zenas BioPharma is trading at a lower price-to-earnings ratio than Myriad Genetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Myriad Genetics	$824.50M	0.50	-$365.90M	-$4.30	N/A
Zenas BioPharma	$10M	109.85	-$377.74M	-$8.47	N/A

Zenas BioPharma has a net margin of 0.00% compared to Myriad Genetics' net margin of -48.24%. Myriad Genetics' return on equity of -8.51% beat Zenas BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Myriad Genetics	-48.24%	-8.51%	-4.48%
Zenas BioPharma	N/A	-99.99%	-58.06%

Summary

Myriad Genetics beats Zenas BioPharma on 9 of the 16 factors compared between the two stocks.

How does Myriad Genetics compare to OPKO Health?

Myriad Genetics (NASDAQ:MYGN) and OPKO Health (NASDAQ:OPK) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, dividends, institutional ownership, analyst recommendations, earnings and valuation.

In the previous week, OPKO Health had 1 more articles in the media than Myriad Genetics. MarketBeat recorded 3 mentions for OPKO Health and 2 mentions for Myriad Genetics. Myriad Genetics' average media sentiment score of 0.84 beat OPKO Health's score of 0.72 indicating that Myriad Genetics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Myriad Genetics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
OPKO Health	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

OPKO Health has lower revenue, but higher earnings than Myriad Genetics. OPKO Health is trading at a lower price-to-earnings ratio than Myriad Genetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Myriad Genetics	$824.50M	0.50	-$365.90M	-$4.30	N/A
OPKO Health	$606.90M	1.82	-$225.68M	-$0.27	N/A

Myriad Genetics has a beta of 1.73, indicating that its stock price is 73% more volatile than the broader market. Comparatively, OPKO Health has a beta of 1.5, indicating that its stock price is 50% more volatile than the broader market.

OPKO Health has a net margin of -36.63% compared to Myriad Genetics' net margin of -48.24%. Myriad Genetics' return on equity of -8.51% beat OPKO Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Myriad Genetics	-48.24%	-8.51%	-4.48%
OPKO Health	-36.63%	-16.78%	-10.98%

Myriad Genetics presently has a consensus price target of $6.50, indicating a potential upside of 47.73%. OPKO Health has a consensus price target of $1.55, indicating a potential upside of 6.16%. Given Myriad Genetics' higher possible upside, equities analysts clearly believe Myriad Genetics is more favorable than OPKO Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Myriad Genetics	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
OPKO Health	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.17

99.0% of Myriad Genetics shares are held by institutional investors. Comparatively, 64.6% of OPKO Health shares are held by institutional investors. 1.9% of Myriad Genetics shares are held by insiders. Comparatively, 49.7% of OPKO Health shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Myriad Genetics beats OPKO Health on 9 of the 17 factors compared between the two stocks.

How does Myriad Genetics compare to Lexicon Pharmaceuticals?

Myriad Genetics (NASDAQ:MYGN) and Lexicon Pharmaceuticals (NASDAQ:LXRX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, media sentiment, analyst recommendations, dividends, earnings and profitability.

Lexicon Pharmaceuticals has a net margin of -37.46% compared to Myriad Genetics' net margin of -48.24%. Myriad Genetics' return on equity of -8.51% beat Lexicon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Myriad Genetics	-48.24%	-8.51%	-4.48%
Lexicon Pharmaceuticals	-37.46%	-18.64%	-11.79%

Myriad Genetics has a beta of 1.73, indicating that its share price is 73% more volatile than the broader market. Comparatively, Lexicon Pharmaceuticals has a beta of 1.07, indicating that its share price is 7% more volatile than the broader market.

99.0% of Myriad Genetics shares are held by institutional investors. Comparatively, 74.7% of Lexicon Pharmaceuticals shares are held by institutional investors. 1.9% of Myriad Genetics shares are held by company insiders. Comparatively, 14.0% of Lexicon Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Lexicon Pharmaceuticals had 1 more articles in the media than Myriad Genetics. MarketBeat recorded 3 mentions for Lexicon Pharmaceuticals and 2 mentions for Myriad Genetics. Myriad Genetics' average media sentiment score of 0.84 beat Lexicon Pharmaceuticals' score of 0.47 indicating that Myriad Genetics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Myriad Genetics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lexicon Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Myriad Genetics currently has a consensus target price of $6.50, indicating a potential upside of 47.73%. Lexicon Pharmaceuticals has a consensus target price of $4.55, indicating a potential upside of 145.95%. Given Lexicon Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Lexicon Pharmaceuticals is more favorable than Myriad Genetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Myriad Genetics	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Lexicon Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Lexicon Pharmaceuticals has lower revenue, but higher earnings than Myriad Genetics. Lexicon Pharmaceuticals is trading at a lower price-to-earnings ratio than Myriad Genetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Myriad Genetics	$824.50M	0.50	-$365.90M	-$4.30	N/A
Lexicon Pharmaceuticals	$49.80M	16.50	-$50.34M	-$0.07	N/A

Summary

Lexicon Pharmaceuticals beats Myriad Genetics on 9 of the 16 factors compared between the two stocks.

How does Myriad Genetics compare to Geron?

Myriad Genetics (NASDAQ:MYGN) and Geron (NASDAQ:GERN) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, earnings, risk, analyst recommendations, institutional ownership, media sentiment and dividends.

99.0% of Myriad Genetics shares are held by institutional investors. Comparatively, 73.7% of Geron shares are held by institutional investors. 1.9% of Myriad Genetics shares are held by insiders. Comparatively, 1.7% of Geron shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Geron had 1 more articles in the media than Myriad Genetics. MarketBeat recorded 3 mentions for Geron and 2 mentions for Myriad Genetics. Myriad Genetics' average media sentiment score of 0.84 beat Geron's score of 0.65 indicating that Myriad Genetics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Myriad Genetics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Geron	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Myriad Genetics has a beta of 1.73, suggesting that its stock price is 73% more volatile than the broader market. Comparatively, Geron has a beta of 0.6, suggesting that its stock price is 40% less volatile than the broader market.

Geron has lower revenue, but higher earnings than Myriad Genetics. Geron is trading at a lower price-to-earnings ratio than Myriad Genetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Myriad Genetics	$824.50M	0.50	-$365.90M	-$4.30	N/A
Geron	$183.88M	4.05	-$83.50M	-$0.11	N/A

Geron has a net margin of -35.48% compared to Myriad Genetics' net margin of -48.24%. Myriad Genetics' return on equity of -8.51% beat Geron's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Myriad Genetics	-48.24%	-8.51%	-4.48%
Geron	-35.48%	-23.31%	-10.08%

Myriad Genetics currently has a consensus price target of $6.50, indicating a potential upside of 47.73%. Geron has a consensus price target of $2.50, indicating a potential upside of 115.52%. Given Geron's higher probable upside, analysts plainly believe Geron is more favorable than Myriad Genetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Myriad Genetics	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Geron	2 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Myriad Genetics beats Geron on 8 of the 15 factors compared between the two stocks.

Get Myriad Genetics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MYGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MYGN vs. The Competition

Export

Metric	Myriad Genetics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$407.07M	$3.24B	$6.47B	$12.54B
Dividend Yield	N/A	2.38%	2.69%	5.22%
P/E Ratio	-1.02	17.78	22.17	24.18
Price / Sales	0.50	315.63	520.79	112.26
Price / Cash	1.14	111.64	41.34	57.13
Price / Book	1.11	6.63	9.84	6.72
Net Income	-$365.90M	$24.20M	$3.57B	$337.19M
7 Day Performance	4.27%	-4.39%	-2.46%	-0.74%
1 Month Performance	N/A	N/A	N/A	-1.69%
1 Year Performance	-16.82%	45.50%	26.49%	33.10%

Myriad Genetics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MYGN Myriad Genetics	3.4127 of 5 stars	$4.40 +2.1%	$6.50 +47.7%	-9.8%	$407.07M	$824.50M	N/A	2,700
MNKD MannKind	4.0977 of 5 stars	$3.53 -6.4%	$8.97 +154.1%	-24.0%	$1.16B	$348.97M	N/A	400	Analyst Forecast
ZBIO Zenas BioPharma	3.6313 of 5 stars	$18.17 -1.3%	$44.29 +143.7%	+82.8%	$1.16B	N/A	N/A	N/A	Analyst Forecast
OPK OPKO Health	1.7308 of 5 stars	$1.40 -4.1%	$1.55 +10.7%	+5.8%	$1.10B	$581.12M	N/A	1,373	Gap Down
LXRX Lexicon Pharmaceuticals	1.9451 of 5 stars	$2.07 -5.0%	$4.55 +119.8%	+192.7%	$968.35M	$49.80M	N/A	140

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MYGN) was last updated on 6/4/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Myriad Genetics (MYGN) Competitors

MYGN vs. MNKD, ZBIO, OPK, LXRX, and GERN

How does Myriad Genetics compare to MannKind?

Summary

How does Myriad Genetics compare to Zenas BioPharma?

Summary

How does Myriad Genetics compare to OPKO Health?

Summary

How does Myriad Genetics compare to Lexicon Pharmaceuticals?

Summary

How does Myriad Genetics compare to Geron?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MYGN vs. The Competition

Myriad Genetics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Myriad Genetics (MYGN) Competitors

MYGN vs. MNKD, ZBIO, OPK, LXRX, and GERN

How does Myriad Genetics compare to MannKind?

Which has better earnings & valuation, MYGN or MNKD?

Do analysts recommend MYGN or MNKD?

Is MYGN or MNKD more profitable?

Which has more volatility and risk, MYGN or MNKD?

Do insiders and institutionals hold more shares of MYGN or MNKD?

Does the media favor MYGN or MNKD?

Summary

How does Myriad Genetics compare to Zenas BioPharma?

Do institutionals and insiders believe in MYGN or ZBIO?

Do analysts rate MYGN or ZBIO?

Which has more volatility and risk, MYGN or ZBIO?

Does the media favor MYGN or ZBIO?

Which has higher earnings and valuation, MYGN or ZBIO?

Is MYGN or ZBIO more profitable?

Summary

How does Myriad Genetics compare to OPKO Health?

Does the media favor MYGN or OPK?

Which has preferable valuation and earnings, MYGN or OPK?

Which has more risk & volatility, MYGN or OPK?

Is MYGN or OPK more profitable?

Do analysts rate MYGN or OPK?

Do insiders and institutionals believe in MYGN or OPK?

Summary

How does Myriad Genetics compare to Lexicon Pharmaceuticals?

Is MYGN or LXRX more profitable?

Which has more risk and volatility, MYGN or LXRX?

Do insiders & institutionals believe in MYGN or LXRX?

Does the media favor MYGN or LXRX?

Do analysts rate MYGN or LXRX?

Which has stronger earnings & valuation, MYGN or LXRX?

Summary

How does Myriad Genetics compare to Geron?

Do insiders and institutionals believe in MYGN or GERN?

Does the media favor MYGN or GERN?

Which has more volatility & risk, MYGN or GERN?

Which has stronger valuation and earnings, MYGN or GERN?

Is MYGN or GERN more profitable?

Do analysts prefer MYGN or GERN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MYGN vs. The Competition

Myriad Genetics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools